KR20230066037A - 전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도 - Google Patents

전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도 Download PDF

Info

Publication number
KR20230066037A
KR20230066037A KR1020237011584A KR20237011584A KR20230066037A KR 20230066037 A KR20230066037 A KR 20230066037A KR 1020237011584 A KR1020237011584 A KR 1020237011584A KR 20237011584 A KR20237011584 A KR 20237011584A KR 20230066037 A KR20230066037 A KR 20230066037A
Authority
KR
South Korea
Prior art keywords
ifn
copd
exacerbations
patients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237011584A
Other languages
English (en)
Korean (ko)
Inventor
리처드 마스덴
필립 몽크
빅토리아 티어
톰 윌킨슨
Original Assignee
시네어젠 리서치 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시네어젠 리서치 리미티드 filed Critical 시네어젠 리서치 리미티드
Publication of KR20230066037A publication Critical patent/KR20230066037A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237011584A 2020-09-08 2021-09-07 전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도 Pending KR20230066037A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2014114.9 2020-09-08
GBGB2014114.9A GB202014114D0 (en) 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
PCT/GB2021/052302 WO2022053792A1 (en) 2020-09-08 2021-09-07 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Publications (1)

Publication Number Publication Date
KR20230066037A true KR20230066037A (ko) 2023-05-12

Family

ID=72841287

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011584A Pending KR20230066037A (ko) 2020-09-08 2021-09-07 전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도

Country Status (7)

Country Link
US (1) US20230241177A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210728A1 (cg-RX-API-DMAC7.html)
JP (1) JP7877300B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066037A (cg-RX-API-DMAC7.html)
CN (1) CN116249545A (cg-RX-API-DMAC7.html)
GB (1) GB202014114D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022053792A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
GB0405634D0 (en) * 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
JP2012512883A (ja) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201820659D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Novel compostions and their use in therapy

Also Published As

Publication number Publication date
EP4210728A1 (en) 2023-07-19
US20230241177A1 (en) 2023-08-03
GB202014114D0 (en) 2020-10-21
JP7877300B2 (ja) 2026-06-22
JP2023540591A (ja) 2023-09-25
WO2022053792A1 (en) 2022-03-17
CN116249545A (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
US11975005B2 (en) Treatment of respiratory diseases
Mainz et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis—results of a multicenter, prospective, randomized, double-blind, controlled trial
JP6911044B2 (ja) 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン2の組合せ
AU2019226190A1 (en) Methods, compounds and compositions for treatment of influenza and parainfluenza patients
US20220193191A1 (en) Lipocalin mutein for treatment of asthma
US20220305077A1 (en) Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1
JP2021516219A (ja) ライノウイルス感染症の予防又は治療のための薬物
US20230241177A1 (en) Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
US11278598B2 (en) Methods for treating diseases associated with respiratory viruses
US7871603B2 (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
JPH06503570A (ja) 肺の悪性腫瘍類を治療するためのアルファーインターフェロンの経口投与
CN101365474B (zh) 用于治疗呼吸道疾病的干扰素λ疗法
WO2022166885A1 (en) Recombinant super-compound interferon (rsifn-co) for treating covid-19 patients with or without symptoms
Rimmer et al. Association of statins with quality of life and olfaction in patients with chronic rhinosinusitis.
CN113384688A (zh) 一种糜蛋白酶在抗冠状病毒中的应用
CA2632032C (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
US20240342239A1 (en) Treatment of non-cystic fibrosis bronchiectasis
JP2021522263A (ja) 肺サーファクタントおよびbpdの予防のためのステロイドを含む治療的組合せ
Sirimanne et al. A Randomized Phase 1 Safety Study of Repeated Doses of Intranasal OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adults: A Potential Treatment for Otitis Media
Başaran et al. Effect of interferon-alpha therapy on serum IgE, IL-4, and sCD23 levels in childhood asthma
Yao et al. Tezepelumab. Anti-TSLP (thymic stromal lymphopoietin), Treatment of severe asthma
KR20240033039A (ko) 호흡기 질환의 치료
WO2022264097A1 (en) Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
JP2023540591A5 (cg-RX-API-DMAC7.html)
WO2020077251A1 (en) Treatment of paranasal sinus disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230404

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240905

Comment text: Request for Examination of Application